European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
Portfolio Pulse from Benzinga Newsdesk
The European Commission has granted conditional marketing authorization to CRISPR Therapeutics' CASGEVY, a CRISPR/Cas9 gene-edited therapy for severe sickle cell disease and transfusion-dependent beta thalassemia in patients 12 and older. This marks a significant milestone for gene-based medicine.
February 13, 2024 | 7:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CRISPR Therapeutics' CASGEVY receives EU approval for treating severe SCD and TDT, marking a significant advancement in gene therapy.
The European Commission's approval of CASGEVY represents a critical regulatory milestone for CRISPR Therapeutics, potentially leading to increased investor confidence and positive market perception. This approval not only validates the company's CRISPR/Cas9 gene-editing technology but also opens up significant market opportunities in the EU for treating severe sickle cell disease and transfusion-dependent beta thalassemia. Given the groundbreaking nature of this therapy and its potential to address unmet medical needs, this news is likely to have a positive short-term impact on CRSP's stock price.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100